Spesolimab

(Spevigo®)

Spevigo®

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 450 mg/7.5 mL (60 mg/mL))
Drug ClassInterleukin-36 receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Spesolimab (Spevigo) is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older, weighing at least 40 kg. It targets the IL36 receptor, offering a specific approach to GPP management.
  • Two systematic reviews/meta-analyses provided information on this drug's safety profile and efficacy in managing GPP flares. However, these studies highlighted a gap in long-term data regarding flare-up prevention.
  • The first study recognized GPP as distinct from plaque psoriasis with no specific treatment guidelines until the advent of Spesolimab. This study emphasized its strong performance but called for further research into its long-term safety and outcomes.
  • The second study was a network meta-analysis comparing the performance of biologics in treating palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP). While Secukinumab showed high efficacy for PP, none of the treatments significantly outperformed placebo based on PPPPGA scores for PPP.
  • In terms of comparative positioning against other drugs like Secukinumab or Guselkumab used to treat similar conditions such as PP/PPP, direct comparisons are challenging due to a lack of head-to-head trials involving Spevigo specifically against these drugs within these conditions.
  • Both studies independently suggest that while current evidence supports the efficacy of newer biologics, including Spesolimab (Spevigo), there is a considerable need for more comprehensive studies focusing on understanding the full potential across varied patient populations over longer periods.